Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

The epidermal growth factor receptor directed antibody, cetuximab, is an effective clinical therapy for patients with colorectal, head and neck and non-small cell lung cancer patients particularly for those with KRAS and BRAF wild type cancers. Treatment in all patients is limited eventually by the...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Yonesaka, Kimio, Zejnullahu, Kreshnik, Okamoto, Isamu, Satoh, Taroh, Cappuzzo, Federico, Souglakos, John, Ercan, Dalia, Rogers, Andrew, Roncalli, Massimo, Takeda, Masayuki, Fujisaka, Yasuhito, Philips, Juliet, Shimizu, Toshio, Maenishi, Osamu, Cho, Yonggon, Sun, Jason, Destro, Annarita, Taira, Koichi, Takeda, Koji, Okabe, Takafumi, Swanson, Jeffrey, Itoh, Hiroyuki, Takada, Minoru, Lifshits, Eugene, Okuno, Kiyotaka, Engelman, Jeffrey A., Shivdasani, Ramesh A., Nishio, Kazuto, Fukuoka, Masahiro, Varella-Garcia, Marileila, Nakagawa, Kazuhiko, Jänne, Pasi A.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2011
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3268675/
https://ncbi.nlm.nih.gov/pubmed/21900593
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.3002442
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια